Mayzent 0.25 MG

 

PI         PL
 

 

Mayzent 2 MG

 

PI         PL
 

Therapeutic indication:

Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease, and active secondary progressive disease, in adults. It is included in the national health basket (NBH) as second line mono therapy for patients with relapsing-remitting multiple sclerosis (RRMS), who have previously experience treatment failure for at least one year and under certain conditions or an a serious adverse event with other DMT or as a first line treatment for patients with an aggressive course of disease

May 04.21 June 2021
×

Medical Information Request

×

Ask Speakers